Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study [0.03%]
化疗后不可切除或转移性软组织肉瘤换用安罗替尼维持治疗：单中心回顾研究
Jie Liu,Yao-Tiao Deng,Yu Jiang
Jie Liu
Background Chemotherapy is an important first-line treatment option in patients with advanced soft tissue sarcoma (STS). Whether maintenance therapy improves survival after chemotherapy is still controversial. Methods We retrospectively ana...
Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy [0.03%]
进口β1在成人T细胞白血病/淋巴瘤治疗过程中调节细胞生长和存活
Chie Ishikawa,Masachika Senba,Naoki Mori
Chie Ishikawa
There is no cure for adult T cell leukemia/lymphoma (ATLL) associated with human T cell leukemia virus type 1 (HTLV-1), and novel targeted strategies are needed. NF-κB and AP-1 are crucial for ATLL, and both are transported to the nucleus ...
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma [0.03%]
回顾分析EGFR突变的非小细胞肺癌患者在奥希替尼引起间质性肺疾病后再次使用奥希替尼的效果
Hiroaki Kodama,Kazushige Wakuda,Michitoshi Yabe et al.
Hiroaki Kodama et al.
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has exhibited efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC). Interstitial lung disease (ILD) is a fata...
Epidermal growth factor-like domain multiple 6 (EGFL6) promotes the migration and invasion of gastric cancer cells by inducing epithelial-mesenchymal transition [0.03%]
表皮生长因子样域多肽6（EGFL6）通过诱导上皮间充质转化促进胃癌细胞的迁移和侵袭
Fu-Chun Huo,Wen-Tao Zhu,Xu Liu et al.
Fu-Chun Huo et al.
Epidermal growth factor-like domain multiple 6 (EGFL6) is implicated in tumor growth, metastasis and angiogenesis, and its ectopic alteration has been detected in aggressive malignancies. However, the pathophysiologic roles and molecular me...
Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma [0.03%]
体外射束放射与缺氧激活前药ICF05016联合在实验性非骨源性粘液样软骨肉瘤模型中的相关性
Elise Maubert,Valérie Weber,Aurélien Voissière et al.
Elise Maubert et al.
Currently, there is no gold standard treatment for Extraskeletal Myxoid Chondrosarcomas (EMC) making wide margin surgical resection the most effective alternative treatment. Nevertheless, in previous preclinical studies our lab demonstrated...
Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma [0.03%]
多西他赛、顺铂和氟尿嘧啶（TPF）方案诱导化疗对局部晚期鼻咽癌的近期结果研究
Shigemasa Takamizawa,Yoshitaka Honma,Naoya Murakami et al.
Shigemasa Takamizawa et al.
There is an unmet need for improving survival outcomes of locally advanced nasopharyngeal carcinoma, for example, T4/ N3 stage disease. To this end, we administered induction chemotherapy (IC) with TPF (docetaxel, cisplatin, and fluorouraci...
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors [0.03%]
crenigacestat（LY3039478），Notch抑制剂，在日本晚期实体瘤患者中进行的1期研究
Toshihiko Doi,Masaomi Tajimi,Joji Mori et al.
Toshihiko Doi et al.
Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid ...
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer [0.03%]
以癌症代谢为基础的SM-88疗法在非转移性生化复发前列腺癌中的二期试验
Benjamin A Gartrell,Mack Roach rd,Avi Retter et al.
Benjamin A Gartrell et al.
Background Androgen deprivation therapy (ADT) is a standard treatment for high-risk biochemically-recurrent, non-metastatic prostate cancer (BRPC) but is not curative and associated with toxicity. Racemetyrosine (SM-88) is an amino-acid ana...
A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib [0.03%]
髋部炎症性肌纤维母细胞瘤中发现LRRFIP1-ALK融合基因及克唑替尼的治疗反应
Weifeng Liu,Qianqian Duan,Lihua Gong et al.
Weifeng Liu et al.
An inflammatory myofibroblastic tumor (IMT) is a rare invasive soft tissue mass with intramuscular penetration that is primarily treated via a surgical procedure. However, with unclear boundaries and a high rate of relapse, there is no stan...
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer [0.03%]
pan-Notch抑制剂crenigacestat (LY3039478)在结合强的松在晚期或转移性癌症患者中的两个高剂量强度方案的一期研究
Analía Azaro,Capucine Baldini,Jordi Rodon et al.
Analía Azaro et al.
Background Crenigacestat is a potent Notch inhibitor that decreases Notch signaling and its downstream biological effects. Here, we report the results from Part F of study 16F-MC-JJCA designed to evaluate the safety, pharmacokinetics (PK), ...